https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683127/
Nutritionist and obesity:brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements
Table 1
Brief overview on compound, mechanism of action, main clinical studies, adverse effects, and drug interactions of the main weight-loss dietary supplements
CompoundMechanism of actionMain clinical studiesAdverse effectsDrug interactionsUsefulness
β-glucans | Increases satiety and total gastrointestinal transit time; slow cholesterol and glucose absorption | [19] | Abdominal pain, bloating, and disturbed defecation, such as urgent diarrhea and/or episodes of chronic constipation | Interaction with immunosuppressants, non-steroidal anti-inflammatory, and antihypertensive drugs | Not significant weight loss |
Bitter orange | Increases energy expenditure and lipolysis, acts as a mild appetite suppressant | [25, 26] | Chest pain, tachycardia, anxiety, dyspnea; increases the risk for hypertension and cerebrovascular diseases when taken with stimulants such as caffeine or caffeine-containing herbs | Increase in blood levels of immunosuppressants, antiretroviral agents, drugs metabolized by the liver (CYP3A4); additive effect with antidepressant depression (MAOIs) and anti-diabetic drugs | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Caffeine | Stimulates thermogenesis and central nervous system, increases fat oxidation and decreases the energy intake | [32, 33] | Nausea, vomiting, tachycardia, seizures, and cerebral edema | Toxic effects for the concomitant administration of caffeine and other drugs metabolized by the CYP1A2, including selective serotonin reuptake inhibitors, antiarrhythmics, MAOIs, lithium, bronchodilators, and quinolones; decrease the effectiveness of alendronate | The effect of caffeine alone on body weight are missing and further research is needed to confirm these findings |
Calcium | Increases lipolysis and fat accumulation, decreases fat absorption by increasing fecal fat excretion | [38–41] | Constipation, increased risk of kidney stones, and interference with zinc and iron absorption | Reduces the absorption of bisphosphonates, levothyroxine, and antibiotics; induces hypercalcemia in association with thiazides cardiotoxicity in association with digoxin | Calcium supplementation did not significantly affect body weight or body fat |
Capsaicin | Increases thermogenesis and energy expenditure; enhances lipolysis in adipocytes, glycogenolysis in the liver, and fat oxidation in muscle; increases satiety by increasing GLP-1 secretion, and reduce energy intake | [46] | Gastrointestinal distress, sweating, flushing, and rhinorrhea | Interferes with antihypertensive, anti-diabetic, anti-anticoagulant drugs, and simvastatin; reduces the efficacy of drugs metabolized by CYP2C19 and CYP3A4 | Its consumption may contribute to weight management through reductions in total energy intake |
Carnitine | Increases mitochondrial β-oxidation of fatty acids and lipolysis; reduces adipogenesis | [53] | Muscle weakness in patients with uremia and seizures in those suffer of epilepsy | Decreases the effectiveness of the supplemented thyroid hormone; increases anticoagulant effects of warfarin | Its consumption may temporarily contribute to weight loss |
Chitosan | Prevents fat absorption, decreases cholesterol absorption, and increases fecal fat excretion | [60, 61] | Allergic reactions, flatulence, bloating, constipation, indigestion, nausea, and heartburn | Potential increase of the anticoagulants; reduces the absorption of fat-soluble vitamins (A, D, E, and K) | Considering the limited studies available, chitosan supplementation cannot be recommended at this time for weight loss |
Chromium | Increases the activity of insulin, regulates eating behavior, mood and food cravings, and stimulates thermogenesis | [65, 66] | Skin irritation, headaches, dizziness, nausea and vomiting, mood changes, watery stools, and weakness | Decreases the serum thyroxine concentration; aspirin and non-steroidal anti-inflammatory drugs increase the risk of adverse effects; potentiates insulin or anti-diabetic drugs | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Coleus forskohlii | Stimulates cAMP levels, fat oxidation, and thermogenesis, activates the hormone-sensitive lipase, reduces appetite | [71, 72] | Increased frequency of bowel movements and loose stools, headache | Decreases the effect of anticoagulant drugs; potentiates the effects of hypotensive drugs; stimulates metabolism of CYP3A substrate drugs | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Conjugated linoleic acid | Increases lipolysis and fatty acid oxidation in skeletal muscle, reduces lipogenesis, promotes apoptosis in adipose tissue, increases UCP-1 and energy expenditure | [79] | Abdominal discomfort and pain, constipation, diarrhea, loose stools, nausea, vomiting, and dyspepsia | Potential interactions with anticoagulant drugs | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Fucoxanthin | Increases energy expenditure, fatty acid oxidation and thermogenesis, inhibits adipocytes differentiation | [84] | Potential risk of thyroid disorders | No drug interactions have been reported | Considering the limited studies available, fucoxanthin cannot be recommended at this time for weight loss |
Garcinia cambogia | Exerts anorexigenic effects, stimulates fatty acid and inhibits cholesterol synthesis | [86–89] | Headache, nausea, upper respiratory tract, and gastrointestinal symptoms | Interacts with anti-diabetic, serotonin-norepinephrine reuptake inhibitors and CYP2B6 substrate drugs; increases risk of rhabdomyolysis with HMG-CoA reductase inhibitors | Garcinia cambogia did not significantly affect body weight or body fat |
Glucomannan | Promotes satiety, delays gastric emptying, and reduces small-bowel transit and cholesterol absorption | [95–97] | Abdominal discomfort, bloating, flatulence, diarrhea, loose stools, and belching and flatulence | Reduces with absorption of antihypertensives, antilipemics, antidiabetics, liposoluble vitamins and anti-obesity agents; increases the enterohepatic circulation of thyroid hormones | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Guar gum | Reduces dietary lipids absorption and gastric emptying, increases satiety | [100] | Abdominal pain and cramps, nausea, diarrhea, flatulence, and increased number of bowel movements | Decreases the absorption of digoxin, aspirin, paracetamol, rosuvastatin, anti-diabetic drugs, corticosteroids, and multivitamins | Guar gum did not significantly affect body weight |
Hoodia Gordonii | Suppresses appetite and adrenal steroidogenesis, exerts antinflammatory | [105] | Dizziness, nausea, disturbance of skin sensation, headache, hypertension, tachycardia, electrocardiogram abnormalities, and blood chemistry abnormalities | Interactions with anti-diabetic drugs and anticoagulants; inhibits CYP3A4 substrate drugs | Hoodia Gordonii did not significantly affect body weight |
Irvingia gabonensis | Reduces fat storage, food intake and gastric emptying; inhibits adipogenesis | [106, 109] | Headache, xerostomia, gastrointestinal complaints, sleep disorder, and flu-like symptoms | May enhance the side effects of anti-diabetic drugs and statins | Considering the limited studies available, Irvingia gabonensis cannot be recommended at this time for weight loss |
Phaseolus vulgaris | Reduces food intake, gastric emptying, carbohydrate digestion and fat storage; stimulates cholecystokinin and GLP-1 release | [110, 111] | Flatulence, constipation or soft stools and headaches | Interactions with anti-diabetic drugs and insulin | Phaseolus vulgaris supplementation showed statistically significant effects on body weight and body fat |
Pyruvate | Increases lipolysis, energy expenditure, thyroxine levels, and ‘futile’ cycling in glycolytic pathways | [116] | Gas, bloating, and diarrhea | Not available | Not enough evidence to recommend the consumption as an adjuvant in weight-loss management |
Raspberry ketone | Reduces adipogenesis, fat storage and appetite | [122] | Cardiotoxicity as well as a teratogenic effect | Interactions with anti-diabetic drugs and anticoagulants | Considering the limited studies available, raspberry ketone cannot be recommended at this time for weight loss |
'대사' 카테고리의 다른 글
암 치료를 위한 암 대사 표적의 새로운 역할 (0) | 2021.09.10 |
---|---|
암 대사 및 치료적 의미의 분자 및 경로에 대한 새로운 통찰력 (0) | 2021.09.09 |
암에서 대사 재프로그래밍을 표적으로 하는 파이토케미칼 (0) | 2021.09.05 |
G6PD: A hub for metabolic reprogramming and redox signaling in cancer (0) | 2021.09.02 |
In cancer, all roads lead to NADPH (0) | 2021.09.02 |